Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H25NO3 |
Molecular Weight | 267.3639 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
InChI
InChIKey=IUBSYMUCCVWXPE-UHFFFAOYSA-N
InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
Molecular Formula | C15H25NO3 |
Molecular Weight | 267.3639 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Mrtoprolol is a beta-adrenergic receptor blocking agent. In vitro and in vivo animal studies have shown that it has a preferential effect
on beta-1 adrenoreceptors, chiefly located in cardiac muscle. Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Mrtoprolol is indicated for the treatment of hypertension, angina pectoris and myocardial infarction
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LOPRESSOR Approved UseHypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). Launch Date2.71296004E11 |
|||
Primary | LOPRESSOR Approved UseHypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). Launch Date2.71296004E11 |
|||
Primary | LOPRESSOR Approved UseHypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). Launch Date2.71296004E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
76 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10741632/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
METOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
279 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10741632/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
METOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10741632/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
METOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9 h |
unknown |
METOPROLOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90% |
unknown |
METOPROLOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5000 mg single, oral Overdose |
unknown, 39 years n = 1 Health Status: unknown Condition: suicide attempt Age Group: 39 years Sex: F Population Size: 1 Sources: |
Disc. AE: Bradycardia... AEs leading to discontinuation/dose reduction: Bradycardia (1 patient) Sources: |
7500 mg single, oral Overdose |
unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: unknown Population Size: 1 Sources: |
Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bradycardia | 1 patient Disc. AE |
5000 mg single, oral Overdose |
unknown, 39 years n = 1 Health Status: unknown Condition: suicide attempt Age Group: 39 years Sex: F Population Size: 1 Sources: |
Death | grade 5, 1 patient Disc. AE |
7500 mg single, oral Overdose |
unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: unknown Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27006091/ Page: 16.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9143866/ Page: 4.0 |
yes [Ki 570 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: coadministration of quinidine 100 mg and immediate release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life; Coadministration of metoprolol with gefitinib resulted in a 35% increase in the metoprolol area under plasma concentration-time curve from time zero to the time of the last quantifiable concentration; paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients; Page: 3.0 |
|||
minor | ||||
minor | ||||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy. | 1994 Oct |
|
Early alterations of polyamine metabolism induced after acute administration of clenbuterol in mouse heart. | 1999 |
|
Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. | 1999 Apr |
|
Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat. | 1999 Nov-Dec |
|
Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. | 2000 Apr |
|
Side effects of beta-blocker treatment for hypertension. | 2000 Jun |
|
Beta-blockade in adriamycin-induced cardiomyopathy. | 2000 Jun |
|
beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. | 2000 May 2 |
|
Syncope in pharmacologically unmasked Brugada syndrome: indication for an implantable defibrillator or an unresolved dilemma? | 2001 Apr |
|
Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. | 2001 Apr 1 |
|
Quantitative structure-retention and retention-activity relationships of beta-blocking agents by micellar liquid chromatography. | 2001 Apr 6 |
|
Enantiomer separation by strong anion-exchange capillary electrochromatography with dynamically modified sulfated beta-cyclodextrin. | 2001 Feb |
|
Metoprolol-induced functional benefit in dilated cardiomyopathy is sustained over four years and favorably influences outcome. | 2001 Feb |
|
Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. | 2001 Feb |
|
Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. | 2001 Feb 1 |
|
Hyperthyroid dementia: clinicoradiological findings and response to treatment. | 2001 Feb 15 |
|
Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. | 2001 Jan |
|
Silent ischemic interval on exercise test is a predictor of response to drug therapy: a randomized crossover trial of metoprolol versus diltiazem in stable angina. | 2001 Jan |
|
Chiral ion-pair chromatography on porous graphitized carbon using N-blocked dipeptides as counter ions. | 2001 Jan 5 |
|
Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. | 2001 Jul |
|
Enantiomeric separation of metoprolol and alpha-hydroxymetoprolol by liquid chromatography and fluorescence detection using a chiral stationary phase. | 2001 Jul 15 |
|
Effect of lipophilicity on in vivo iontophoretic delivery. II. Beta-blockers. | 2001 Jun |
|
Circadian variation of heart rate variability and the rate of autonomic change in the morning hours in healthy subjects and angina patients. | 2001 Jun |
|
Cardiac autonomic denervation and functional response to neurotoxins during acute experimental Chagas' disease in rats. | 2001 Jun 20 |
|
Metoprolol attenuates postischemic depressed myocardial function in papillary muscles isolated from normal and postinfarction rat hearts. | 2001 Jun 22 |
|
Behavioral-independent features of complex heartbeat dynamics. | 2001 Jun 25 |
|
A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. | 2001 Mar |
|
Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). | 2001 Mar |
|
Angerlike behavioral state potentiates myocardial ischemia-induced T-wave alternans in canines. | 2001 May |
|
Carvedilol in the treatment of chronic heart failure. | 2001 May |
|
Economic impact of beta blockade in heart failure. | 2001 May 7 |
|
Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. | 2001 May-Aug |
Sample Use Guides
Hypertension
The dosage of Lopressor should be individualized. Lopressor should be taken with or immediately following meals.
The usual initial dosage is 100 mg daily in single or divided doses, whether used alone or added to a diuretic. The dosage may be
increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of
any given dosage level will be apparent after 1 week of therapy. The effective dosage range is 100-450 mg per day. Dosages above
450 mg per day have not been studied. While once-daily dosing is effective and can maintain a reduction in blood pressure throughout
the day, lower doses (especially 100 mg) may not maintain a full effect at the end of the 24-hour period, and larger or more frequent
daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine
whether satisfactory control is being maintained throughout the day. Beta1 selectivity diminishes as the dose of Lopressor is increased.
Angina Pectoris
The dosage of Lopressor should be individualized. Lopressor should be taken with or immediately following meals.
The usual initial dosage is 100 mg daily, given in two divided doses. The dosage may be gradually increased at weekly intervals
until optimum clinical response has been obtained or there is pronounced slowing of the heart rate. The effective dosage range is
100-400 mg per day. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, the dosage should be
reduced gradually over a period of 1-2 weeks (see WARNINGS).
Myocardial Infarction
Early Treatment: During the early phase of definite or suspected acute myocardial infarction, treatment with Lopressor can be
initiated as soon as possible after the patient’s arrival in the hospital. Such treatment should be initiated in a coronary care or similar
unit immediately after the patient’s hemodynamic condition has stabilized.
Treatment in this early phase should begin with the intravenous administration of three bolus injections of 5 mg of Lopressor each; the
injections should be given at approximately 2-minute intervals. During the intravenous administration of Lopressor, blood pressure,
heart rate, and electrocardiogram should be carefully monitored.
In patients who tolerate the full intravenous dose (15 mg), Lopressor tablets, 50 mg every 6 hours, should be initiated 15 minutes after
the last intravenous dose and continued for 48 hours. Thereafter, patients should receive a maintenance dosage of 100 mg twice daily
(see Late Treatment below).
Patients who appear not to tolerate the full intravenous dose should be started on Lopressor tablets either 25 mg or 50 mg every
6 hours (depending on the degree of intolerance) 15 minutes after the last intravenous dose or as soon as their clinical condition
allows. In patients with severe intolerance, treatment with Lopressor should be discontinued (see WARNINGS).
Late Treatment: Patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction,
patients who appear not to tolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other
reason should be started on Lopressor tablets, 100 mg twice daily, as soon as their clinical condition allows. Therapy should be
continued for at least 3 months. Although the efficacy of Lopressor beyond 3 months has not been conclusively established, data from
studies with other beta blockers suggest that treatment should be continued for 1-3 years.
Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration,
whenever solution and container permit.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27300117
0.01 to 0.1 uM metoprolol increased osteoblast proliferation, alkaline phosphatase activity, and calcium mineralization, and promoted the expression of osteogenic genes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 21:59:10 UTC 2023
by
admin
on
Thu Jul 06 21:59:10 UTC 2023
|
Record UNII |
GEB06NHM23
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07FX03
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07BB52
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
LIVERTOX |
NBK547984
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07BB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
FDA ORPHAN DRUG |
804220
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07AB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-VATC |
QC07BB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07FB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07CB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-VATC |
QC07AB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07FX05
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-VATC |
QC07AB52
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
NDF-RT |
N0000175556
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-VATC |
QC07CB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-VATC |
QC07FB02
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
NDF-RT |
N0000000161
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07AB52
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
FDA ORPHAN DRUG |
804320
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-VATC |
QC07BB52
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
||
|
WHO-ATC |
C07FB13
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
253-483-7
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
ALTERNATIVE | |||
|
51384-51-1
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
METOPROLOL
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
GEB06NHM23
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
257-166-4
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
DTXSID2023309
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
37350-58-6
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
SUPERSEDED | |||
|
100000076066
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
D008790
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
Metoprolol
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
CHEMBL13
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
GEB06NHM23
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
6918
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB00264
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
6904
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
6531
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
553
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
SUB14568MIG
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
M7498
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | Merck Index | ||
|
1786
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
C61845
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
3471
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY | |||
|
54163-88-1
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
SUPERSEDED | |||
|
4171
Created by
admin on Thu Jul 06 21:59:12 UTC 2023 , Edited by admin on Thu Jul 06 21:59:12 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
O-demethylmetoprolol is a pharmacologically active urinary metoprolol metabolite that has 5 to 10X less potent than metoprolol.
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
Alpha-hydroxymetoprololhas 5 to 10X less potent than metoprolol.
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC |
|
||